Clinical and Cytogenetic Characteristics of Children With Leukemia 20-Year Retrospective Study.
Child
Humans
Retrospective Studies
Core Binding Factor Alpha 2 Subunit
/ genetics
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Chromosome Aberrations
Translocation, Genetic
Cytogenetic Analysis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ genetics
Leukemia, Myeloid, Acute
/ genetics
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
22
11
2021
accepted:
26
06
2022
pubmed:
1
9
2022
medline:
3
3
2023
entrez:
31
8
2022
Statut:
ppublish
Résumé
Acute leukemias are the most common malignant diseases in childhood. The aims of this retrospective cohort study were to investigate the frequency of cytogenetic abnormalities in acute pediatric leukemia; the correlation between cytogenetic abnormalities and 5-year survival; and the correlation between cytogenetic abnormalities and clinical and laboratory features. We included 105 patients; acute lymphoblastic leukemia (ALL) had 80.9% patients, B-cell lineage ALL (B-ALL) 84.7% of them, and T-cell lineage (T-ALL) 15.3%. The overall 5-year survival for B-ALL was 85.9% and for T-ALL was 84.6%. The most common cytogenetic abnormalities in patients with B-ALL were t(12;21)(p13.2;q22.1); ETV6-RUNX1 with 22.2% and hyperdiploidy with 19.4%. Our survival analysis showed that t(12;21)(p13.2;q22.1); ETV6-RUNX1 and t(1;19)(q23;p13.3); TCF3-PBX1 had the best 5-year survival with 100% of patients surviving, whereas t(v;11q23.3); KMT2A rearranged had the worst 5-year survival of just 33.3% of patients surviving after 5 years. We found no difference in 5-year survival in B-ALL when comparing clinical features. Acute myelogenous leukemia had 20 patients with 70.6% 5-year survival. The most common cytogenetic abnormality in acute myelogenous leukemia was t(8;21)(q21;q22.1); RUNX1-RUNX1T1 (20%). In conclusion, this study showed the correlation of different cytogenetic abnormalities with 5-year survival in B-ALL patients. Such correlation was not found when comparing clinical features and 5-year survival of patients with B-ALL. This emphasized the significance of cytogenetic analysis in pediatric leukemia.
Identifiants
pubmed: 36044298
doi: 10.1097/MPH.0000000000002529
pii: 00043426-202303000-00013
doi:
Substances chimiques
Core Binding Factor Alpha 2 Subunit
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e161-e166Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–1043.
Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83–103.
Svendsen AL, Feychting M, Klaeboe L, et al. Time trends in the incidence of acute lymphoblastic leukemia among children 1976-2002: a population-based Nordic study. J Pediatr. 2007;151:548–550.
Feng Q, Smith AJ De, Vergara-lluri M, et al. Trends in acute lymphoblastic leukemia incidence in the United States by race/ethnicity from 2000 to 2016. Am J Epidemiol. 2021;190:519–527.
Shah A, Coleman MP. Increasing incidence of childhood leukaemia: a controversy re-examined. Br J Cancer. 2007;97:1009–1012.
Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood. 2004;104:2690–2696.
Gatta G, Capocaccia R, Stiller C, et al. Childhood cancer survival trends in Europe: a EUROCARE working group study. J Clin Oncol. 2005;23:3742–3751.
Gamis AS, Alonzo TA, Perentesis JP, et al. Children’s Oncology Group’s 2013 blueprint for research: acute myeloid leukemia. Pediatr Blood Cancer. 2013;60:964–971.
Schwab C, Harrison CJ. Acute lymphoblastic leukaemia. Methods Mol Biol. 2011;730:99–117.
Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009;144:147–156.
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
Barch MJ, Arsham MS, Lawce HJ The ACT Cytogenetics Laboratory Manual. New Jersey: Wiley; 1997.
Petkovic I, Josip K, Nakic M, et al. Cytogenetic, cytomorphologic, and immunologic analysis in 55 children with acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1996;88:57–65.
Forestier E, Heyman M, Andersen MK, et al. Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol. 2008;140:665–672.
Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11:429–438.
Campbell M, Castillo L, Cecilia Riccheri D, et al. A Randomized Trial of the I-BFM-SG for the Management of Childhood non-B Acute Lymphoblastic Leukemia STEERING COMMITTEE. 2009.
Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol. 2001;113:103–114.
Chennamaneni R, Gundeti S, Konatam ML, et al. Impact of cytogenetics on outcomes in pediatric acute lymphoblastic leukemia. South Asian J Cancer. 2018;07:263–266.
Vardiman JW, Thiele JA. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2008;114:937–952.
Rubin C, Rowley J Nathan DG, Oski FA. Chromosomal abnormalities in childhood malignant diseases. Hematology of Infancy and Childhood, 4th ed. Philadelphia: WB Saunders; 1993:1288–1318.
Tubergen D, Bleyer A, Ritchey K, et al. Kliegman RM, Stanton BMD, St. Geme JW. The Leukemias. Nelson Textbook of Pediatrics, 20th ed. Amsterdam: Elsevier; 2015:2437–2445.
Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359:1909–1915.
Harrison CJ, Moorman AV, Broadfield ZJ, et al. Three distinct subgroups of hypodiploidy in lymphoblastic leukaemia. Br J Haematol. 2004;125:552–559.
Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC publications; 2008.
Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355:165–169.
Creutzig U, Van Den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3167–3205.
Mckenney AH, Cleary M, Arber D Pizzo PA, Poplack DG. Pathology and molecular diagnosis of leukemias and lymphomas. Principles and Practice of Pediatric Oncology, 7th ed. Philadelphia: Wolters Kluwer; 2015:139–164.
Redner A, Kessel R Fish J, Lipton J, Lanzkowsky P. Acute myeloid leukemia. Lanzkowsky’s Manual of Pediatric Hematology and Oncology, 6th ed. Amsterdam: Elsevier; 2016:390–406.